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Short Communication
Suppression of plasma 6-keto-prostaglandin F1, and
13,14-dihydro-15-keto-prostaglandin F2, by
aminoglutethimide in advanced breast cancer
A.L. Harris', M.D. Mitchell2, I.E. Smith & T.J. Powles
Royal Marsden Hospital, Fulham Road, London SW3 6JJ.
Human breast cancers have been shown to produce
prostaglandins PGE2 and PGF2a in vitro (Greaves
et al., 1980; Rolland et al., 1980a; Bennett et al.,
1980a; Dowsett et al., 1976) and raised levels are
found in blood draining the tumours in patients
(Stamford et al., 1980). Breast cancer explants in
vitro produce osteolysis, partly by a PG-mediated
mechanism (Powles et al., 1976; Bennett et al.,
1975; Dowsett et al., 1976). Prostaglandins PGE2,
PGF2. and prostacyclin are potent oestelytic agents
in vitro (Raisz et al., 1977; Bennett et al., 1980b).
Aminoglutethimide is an effective endocrine
therapy in advanced postmenopausal breast cancer
producing an increased response rate in bone
metastases compared with tamoxifen (Smith et al.,
1981). Even patients with progressive bone
metastases may have pain relief (Harris et al.,
1982). Aminoglutethimide inhibits several
cytochrome P450-containing enzymes, including
adrenal desmolase and 1l-J-hydroxylase (Dexter ef
al., 1967; Faglia et al., 1971) and peripheral
aromatase (Santen et al., 1978). Metyrapone
inhibits 11-,B-hydroxylase and also prostaglandin
synthetase, which is associated with cytochrome
P450 (Maclouf et al., 1977). Because of the marked
effects of aminoglutethimide on bone metastases
and its similarity to metyrapone, we measured PG
levels in patients treated with aminoglutethimide.
The stable metabolites of PGF2. (13,14-dihydro-15-
keto-prostaglandin F2., PGFM) and prostacyclin
(6-keto-prostaglandin Fl, 6-keto-PGF1) were
measured before and during treatment.
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Twenty-eight patients with advanced
postmenopausal breast cancer were treated with
aminoglutethimide 250mg x 3 daily plus
replacement doses of hydrocortisone (20mg twice
daily). After 2 weeks the aminoglutethimide was
increased to 250mg x 4 daily and the hydro-
cortisone continued. Response was assessed by
standard UICC criteria (Hayward et al., 1977), with
a duration of 3 months from start of treatment
required for complete or partial response and stable
disease. There were 2 complete responses, 10 partial
responses and 1 disease stabilisation. Fifteen
patients had progressive disease. The pretreatment
characteristics of the patients are shown in Table I.
None of the patients had received anti-
inflammatory analgesics in the month before
Table I Pretreatment characteristics of 28 patients
treated with aminoglutethimide
Responders Non-responders
(13) (15)
Age (years)
mean (s.d.) 54 (7) 52 (11)
median 54 51
Time since last
menstrual period
(years)
mean (s.d.) 6.7 (7.7) 6.2 (6.7)
median 5 5
Tumour-free interval
(months)
mean (s.d.) 46 (28) 36 (48)
median 51 24
Weight (kg)
mean (s.d.) 68 (10.5) 57 (6.3)
median 67 56
Sites of recurrence
Soft tissue/nodes 9 12
Pleura/lung 3 5
Bone 5 5
Liver 1 I
Previous endocrine
therapy 5 4
Previous chemotherapy 2 1
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treatment. Ten ml blood samples were taken before
treatment and after 1 month, and collected in tubes
at 0°C containing 0.1 ml EDTA (70mgml -1),
0.1 ml acetylsalicyclic acid (5mgml -1 saturated
solution). The samples were spun at 1500g and
stored at -20°C until assay in one batch. Samples
were collected over a 6-month period, and stored
for a maximum of 9 months. The samples were
assayed by a new immunoassay that did not require
prior extraction or chromatography (Strickland et
al., 1982). Eleven patients who had simple
mastectomy and involved lymph nodes had blood
samples taken 6 weeks after the operation as
controls.
In all but one non-responding patient with
progressing liver secondaries, both 6-keto-PGF1a,
and PGFM fell on treatment (Figure 1). On
treatment, levels were significantly lower than in
post mastectomy controls (P<0.001). The
pretreatment levels of PGs did not differ
significantly from controls (Table II). The
percentage suppression of6-keto-PGF1,, was greater
in both responders and non-responders than that of
PGFM (Table II). The levels of PGs in patients
with bone secondaries did not differ from those
without clinical and radiological evidence of bone
secondaries (Table II). Two other patients received
flurbiprofen 200mg 3 x daily alone and their
PGFM and 6-keto-PGF1. levels fell into the lower
range of those treated with aminoglutethimide.
Table II Prostaglandin suppression in patients receiving
aminoglutethimide
(n) 6KFI,, PGFM
Responders (13)
% of baseline 50+21 (<0.001) 76+18 (<0.001)
mean +s.d. (P)
Non-responders (15)
% of baseline 49+36 (<0.001) 67+20 (<0.001)
mean +s.d. (P)
Bone secondaries (10)
pretreatment
(pgml-1) 134+39 190+29
mean +s.d.
No bone
secondaries (18)
pretreatment
(pgml-1) 147+52 205+44
mean +s.d.
Controls (11)
pgml-1 126+56 198+48
mean +s.d.
6KF1U, 6-keto-PGF1,,
PGFM, 13,14-dihydro-15-keto-protaglandin F2a.
P value is paired t-test comparing pre-treatment values
with post treatment values of PGFM or 6KF,a.
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Figure 1 (a) 6-keto-prostaglandin Fl,. (6KF,,) and (b)
13,14-dihydro-15-keto-prostaglandin F2C, (PGFM)
levels before and after 1 month of treatment with
aminoglutethimide. Individual points are post-
mastectomy controls receiving no drugs.
Aminoglutethimide and hydrocortisone produce a
suppression of 6-keto-PGF , to 50% of basal levels.
Oestrone is suppressed to the same degree by
aminoglutethimide and is supposed to be the main
mode of action of the drug.
All the patients were receiving a replacement
dose of hydrocortisone but is is unlikely that thisPROSTAGLANDIN SUPPRESSION BY AMINOGLUTETHIMIDE IN BREAST CANCER 597
caused the PG suppression. We have already shown
that this dose of hydrocortisone does not change
cortisol levels in patients (Harris et al., 1983) and
hydrocortisone is not a potent anti-inflammatory
steroid. The anti-PG effect of steroids is mediated
by stimulating the release of the phospholipase A2
inhibitor macrocortin/lipomodulin. In vitro, this
requires higher cortisol levels for its increased
production than occurred in the patients (Blackwell
et al., 1980; Hirata et al., 1980).
Tamoxifen has a direct effect on prostaglandin
synthesis by human breast cancer in vitro (Ritchie,
1980), but the concentration required to inhibit
PGE production by 47% (5 x 10 5M) was 100
times greater than the levels in plasma from
patients (5 x 10-7M, Wilkinson et al., 1980). In
contrast to tamoxifen, aminoglutethimide has never
been reported to produce a hypercalcaemic "flare",
suggesting that the anti-PG effects of tamoxifen in
vitro may not be relevant clinically.
In many animal reproductive systems, oestrogens
can stimulate PG production by the target organ,
although progesterone is also required (Barcikowski
et al., 1974; Robinson et al., 1976; Fenwick et al.,
1977; Caldwell et al., 1972). It is possible therefore
that oestrogen suppression could have produced a
secondary indirect fall in PGs. If breast cancer
tissue was the main source of PGs, this is an
unlikely mechanism because the fall of PG levels
was the same in responders and non-responders to
aminoglutethimide. Other endocrine responsive
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